Collegium Pharmaceutical, Inc. COLL EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Collegium Pharmaceutical, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s EBITDA margin?
- Collegium Pharmaceutical, Inc. (COLL) reported EBITDA margin of 31.1% in Q1 2026.
- How has Collegium Pharmaceutical, Inc.'s EBITDA margin changed year-over-year?
- Collegium Pharmaceutical, Inc.'s EBITDA margin decreased by 37.8% year-over-year, from 50% to 31.1%.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s EBITDA margin?
- Over 5 years (2020 to 2025), Collegium Pharmaceutical, Inc.'s EBITDA margin has grown at a 5.2% compound annual growth rate (CAGR), from 23.8% to 30.7%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.